
Please try another search
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Name | Age | Since | Title |
---|---|---|---|
Samuel L. Barker | 79 | 2000 | Independent Director |
Raymond Debbane | 67 | 2007 | Independent Chairman of the Board |
Diane E. Sullivan | 61 | 2023 | Independent Director |
Alan Sheffer Nies | 86 | 2003 | Chairman of Medical Advisory Board |
Christopher J. Sobecki | 65 | 2007 | Independent Director |
Judith Lea Swain | 75 | 2007 | Independent Director |
Philippe J. Amouyal | 65 | 2007 | Independent Director |
Michael S. Exton | 55 | 2024 | CEO & Director |
Ivan H. Cheung | 49 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review